Lilly buys in another PI3Kα inhibitor
Scorpion's STX-478 becomes at least the third shot Lilly has taken at PI3Kα.
Arvinas and Pfizer turn away from Ibrance
In first-line breast cancer vepdegestrant will be combined with Pfizer’s investigational CDK4 inhibitor atirmociclib.
Celcuity goes early with its Pfizer cast-off
The company is to start a first-line phase 3 breast cancer trial of gedatolisib, as second-line data approach.
Bicycle has a wobble
Zelenectide looks uncompetitive versus Padcev in bladder cancer, while elsewhere a biomarker strategy beckons.
Elevation brings Synaffix on board in HER3
But the group is going up against the likes of Merck/Daiichi, Bristol Myers Squibb and BioNTech.
SABCS 2024 – Ember-3 dims hopes for Lilly’s SERD
Imlunestrant monotherapy only works in ESR1 mutants, but a Verzenio combo is better in all-comers.
